879091-80-2

Basic information

• Product Name: [4-Chloro-5-fluoro-2-(3-Methoxy-2- Methyl-phenoxy)-benzyl]MethylaMine Hydrochloride
• Synonyms: [4-Chloro-5-fluoro-2-(3-Methoxy-2- Methyl-phenoxy)-benzyl]MethylaMine Hydrochloride
• CAS NO: 879091-80-2
• Molecular Formula: C16H18Cl2FNO2
• Molecular Weight: 346.2240232
• EINECS: -0
• Mol File: 879091-80-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [4-Chloro-5-fluoro-2-(3-Methoxy-2- Methyl-phenoxy)-benzyl]MethylaMine Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: [4-Chloro-5-fluoro-2-(3-Methoxy-2- Methyl-phenoxy)-benzyl]MethylaMine Hydrochloride(879091-80-2)
• EPA Substance Registry System: [4-Chloro-5-fluoro-2-(3-Methoxy-2- Methyl-phenoxy)-benzyl]MethylaMine Hydrochloride(879091-80-2)

Safety Data

• Hazardous Substances Data: 879091-80-2(Hazardous Substances Data)

Usage

General Description

[4-Chloro-5-fluoro-2-(3-Methoxy-2- Methyl-phenoxy)-benzyl]MethylaMine Hydrochloride is a chemical compound derived from benzylamine and features a 4-chloro-5-fluoro-2-(3-methoxy-2-methyl-phenoxy)benzyl group. It is commonly found in pharmaceutical research and is thought to have potential therapeutic applications due to its structural properties. As a hydrochloride salt, it has enhanced stability and solubility, making it easier to handle and incorporate into formulations. [4-Chloro-5-fluoro-2-(3-Methoxy-2- Methyl-phenoxy)-benzyl]MethylaMine Hydrochloride's specific properties and potential uses may require further investigation and testing in various scientific and medical contexts.

Upstream product

• 921213-28-7 4-chloro-5-fluoro-2-(3-methoxy-2-methyl-phenoxy)-N-methyl-benzamide 

Relevant articles and documents

A scalable synthesis of CE-157119 HCl Salt, an SRI/5-HT2A antagonist

A scalable synthesis of CE-157119 HCl salt (1), an SRI/5-HT2A antagonist, was developed via the regioselective SNAr etherification between a phenol and an N-methylamide. This early development route shortened the original 5-step synt

Therapeutic diphenyl ether ligands

This invention is directed to compounds of formula Ia, Ib or Ic and to pharmaceutical compositions thereof: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.